Dose-finding and phase 2 study of weekly paclitaxel (taxol) and cisplatin combination in treating Chinese patients with advanced nonsmall cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 5, 2005, Pages 508-512

  Chen, Chih Hung ^a   Chang, John W C ^a   Lee, Cheng Huei ^a   Tsao, Thomas C Y ^b,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c NONE   (Taiwan)

Author keywords

Chemotherapy; Cisplatin; Nonsmall cell lung cancer; Paclitaxel; Response

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYALGIA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; RASH; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TAXOIDS;

EID: 26444455952     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000182419.47882.51     Document Type: Article

References (22)

1. Department of Health, ROC. Cancer Registry Annual Report. 1997.
2. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in a dvanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest. 1994;106:861-865.
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J. 1995;311:899-909.
4. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665-667.
5. Jordan MA, Wendell K, Gardiner S, et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 1996;56:816-825.
6. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 1996;2:1843-1849.
7. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18:623-631.
8. Hainsworth JD, Urba WJ, Hon JK, et al. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial. Eur J Cancer. 1998;34:654-658.
9. Schiller JH, Harrington D, Belani CP, et al. Comparison of four cmotheraphyhe-regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
10. Helson L, Helson C, Malik S, et al. A saturation threshold for taxol cytotoxicity in human glial and neuroblastoma cells. Anticancer Drugs. 1993;4:487-490.
11. Liebmann JE, Cook JA, Lipschultz C, et al. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer. 1993;68:1104-1109.
12. Georgiadis MS, Russell EK, Gazdar AF, et al. Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin Cancer Res. 1997;3:449-454.
13. Rowinsky EK. The taxanes: dosing and scheduling considerations. Oncol. 1997;11:7-19.
14. Huizing MT, Keung AC, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 1993;11:2127-2135.
15. Rowinsky EK, Wright M, Monsarrat B, et al. Taxol: pharmacology, metabolism and clinical implications. Cancer Surv. 1993;17:283-304.
16. Rowinsky EK, Chaudhry V, Forastiere AA, et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol. 1993;11:2010-2020.
17. Chang AY, Rubins J, Asbury R, et al. Weekly paclitaxel in advanced non-small cell lung cancer. Semi Oncol. 2001;28:10-13.
18. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol. 1997;15:187-192.
19. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infasions in the treatment of metastatic breast cancer. J Clin Oncol. 1998;16:3353-3361.
20. Abratt RP, Sandler A, Crino L, et al. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Semi Oncol. 1998;25:35-43.
21. Chen CH, Chang WC, Lin MC, et al. Phase II study of paclitaxel (Genaxol) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2002;38:91-96.
22. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003;21:2933-2939.